Treatment

The phase 3 TRIDENT trial found that starting Tumor Treating Fields (TTFields) during chemoradiation did not improve overall survival for patients with newly diagnosed glioblastoma compared with the current standard of starting treatment during the maintenance phase. The global study enrolled 981 patients. Median overall survival was 17.7 months in the early-start group and 17.5 […]

Myriad Genetics has expanded the availability of its Precise™ MRD Test for patients with breast, colorectal, and renal cancers. The personalized blood test uses whole-genome sequencing to track up to 1,000 tumor-specific genetic changes, helping detect minimal residual disease (MRD), even in cancers that release very little DNA into the bloodstream. The expansion is supported

The National Comprehensive Cancer Network (NCCN) has updated its bladder cancer guidelines to recommend considering circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing after bladder removal surgery for patients with muscle-invasive bladder cancer (MIBC). This is the first time the NCCN has recognized ctDNA-MRD as both a prognostic and predictive biomarker for this disease.

Patients with previously treated metastatic colorectal cancer may benefit from a new combination therapy of zanzalintinib and the immunotherapy drug Tecentriq, according to results from the Phase 3 STELLAR-303 trial. The study enrolled 901 patients whose cancer had progressed after standard treatments. Among all patients in the trial, the combination reduced the risk of death

A first-in-human Phase 1 study presented at the 2026 EHA Congress has reported encouraging results for CT0596, an off-the-shelf CAR T-cell therapy designed for patients with heavily pretreated relapsed or refractory multiple myeloma and primary plasma cell leukemia. Unlike traditional CAR T-cell treatments that are made from a patient’s own cells, CT0596 uses donor cells

Researchers have identified a promising new way to weaken pancreatic cancer by targeting a protein called IL1RAP. Pancreatic tumors depend on an inflammatory network within their surrounding environment to grow, evade the immune system, and resist treatments such as chemotherapy and immunotherapy. IL1RAP acts as a key control point in this network, and blocking it

For patients with KRAS-mutant metastatic colorectal cancer whose disease progresses after two lines of treatment, third-line therapies can extend survival, but the benefits are often measured in months. As a result, doctors must carefully weigh treatment effectiveness, side effects, and quality of life when selecting therapy. Two commonly used options are trifluridine/tipiracil (Lonsurf) plus bevacizumab

The Phase 3 STELLAR-303 trial tested zanzalintinib plus atezolizumab against regorafenib in patients with previously treated, non-MSI-high metastatic colorectal cancer. The study produced mixed results but achieved its main goal in the overall patient population. The combination did not significantly improve overall survival in patients without active liver metastases, although survival was longer than with

A growing body of evidence shows that starting treatment before surgery, known as a neoadjuvant-first approach, is helping more patients with locally advanced or borderline resectable pancreatic cancer become eligible for surgery and achieve longer survival. Experts emphasize that the best outcomes come from combining chemotherapy, radiation, surgery, and multidisciplinary care rather than relying on

Six-year follow-up data from the GARNET trial show that the immunotherapy drug Dostarlimab-gxly continues to provide durable benefits for patients with advanced or recurrent dMMR/MSI-H endometrial cancer who previously had limited treatment options after platinum-based chemotherapy. At a median follow-up of nearly 69 months, the overall response rate remained 45.5%, while complete responses increased from